Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
https://www.zacks.com/stock/news/2195640/merck-s-mrk-keytruda-lynparza-combo-fails-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195640
Dec 08, 2023 - After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
0
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
https://www.zacks.com/stock/news/2195115/pharvaris-phvs-stock-up-18-on-hae-drug-meeting-study-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195115
Dec 07, 2023 - Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.
0
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
0
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
https://www.zacks.com/stock/news/2194285/pfizer-pfe-arvinas-post-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194285
Dec 06, 2023 - Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
0
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
https://www.zacks.com/stock/news/2193796/alterity-athe-up-on-preclinical-parkinson-s-treatment-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193796
Dec 05, 2023 - Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
0
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193794
Dec 05, 2023 - Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
0
Centene (CNC) Wins Contract From Arizona's Medicaid Agency
https://www.zacks.com/stock/news/2193148/centene-cnc-wins-contract-from-arizona-s-medicaid-agency?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193148
Dec 04, 2023 - Centene's (CNC) Arizona subsidiary has been chosen by the AHCCCS to improve health outcomes for the state's ALTCS-E/PD members and further solidify statewide presence.
0
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
https://www.zacks.com/stock/news/2193099/roche-rhhby-to-acquire-obesity-drug-maker-carmot-for-2-7b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193099
Dec 04, 2023 - Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
0
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
https://www.fool.com/investing/2023/12/02/everyone-is-talking-about-this-stock-is-it-a-good/?source=iedfolrf0000001
Dec 02, 2023 - This company famously helps manage a prevalent chronic illness.
0
An Important History Lesson for Gene-Editing Investors
https://www.fool.com/investing/2023/12/02/an-important-history-lesson-for-gene-editing-inves/?source=iedfolrf0000001
Dec 02, 2023 - Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
0